We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Markers in Male Reproductive Impairments Causing Miscarriages

By LabMedica International staff writers
Posted on 21 Feb 2019
Print article
Image: Halosperm is an in vitro diagnostic kit that allows the measurement of DNA fragmentation in a fast, easy, and reproducible manner, without the need for complex laboratory equipment (Photo courtesy of Halotech DNA SL).
Image: Halosperm is an in vitro diagnostic kit that allows the measurement of DNA fragmentation in a fast, easy, and reproducible manner, without the need for complex laboratory equipment (Photo courtesy of Halotech DNA SL).
Recurrent pregnancy loss, (RPL) affecting 1% to 2% of couples, is defined as ≥3 consecutive pregnancy losses before 20-week' gestation. Women with RPL are routinely screened for etiological factors, but routine screening of male partners is not currently recommended.

Sperm DNA plays a critical role in placentation, so it is biologically plausible that impairments in male reproductive function could increase the risk of RPL. Recent studies suggest that male partners affected by RPL have impaired sperm quality with reduced total motility and morphology and increased sperm DNA damage.

A team of hospital based scientists collaborating with the Imperial College London (London, UK) enrolled 50 men who were partners of women with RPL and 63 men as controls. The controls were slightly younger that the test subjects and were mainly of Caucasian descent. All sperm samples were analyzed within the Department of Andrology, Hammersmith Hospital (London, UK). Sperm morphology was analyzed on Papanicolaou pre-stained slides with Kruger strict criteria.

Semen reactive oxygen species (ROS) were measured with a validated in-house chemiluminescent assay. Each sample was gently mixed immediately before taking luminometer readings. DNA fragmentation was measured with the validated Halosperm method. Morning blood samples were analyzed for serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, testosterone, and sex hormone–binding globulin.

The scientists reported that total sperm motility, progressive sperm motility, and normal morphology were all reduced in the RPL group versus controls. Mean ±SE morning serum testosterone (nmol/L) was 15% lower in RPL than in controls (controls, 19.0 ± 1.0; RPL, 16.0 ± 0.8). Mean ±SE serum estradiol (pmol/L) was 16% lower in RPL than in controls (controls, 103.1 ± 5.7; RPL, 86.5 ± 3.4). Serum luteinizing hormone and follicle-stimulating hormone were similar between groups. Mean ±SE ROS (relative light units (RLU)/sec/106 sperm) were 4-fold higher in RPL than in controls (controls, 2.0 ± 0.6; RPL, 9.1 ± 4.1). Mean ± SE sperm DNA fragmentation (%) was 2-fold higher in RPL than in controls (controls, 7.3 ± 1.0; RPL, 16.4 ± 1.5).

The authors concluded that the data suggested that male partners of women with RPL have impaired reproductive endocrine function, increased levels of semen ROS, and sperm DNA fragmentation. Routine reproductive assessment of the male partners may be beneficial in RPL. The study was published in the January 2019 issue of the journal Clinical Chemistry.

Related Links:
Imperial College London
Hammersmith Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.